Concomitant occurrence of BCR-ABL and JAK2V617F mutation

Blood

Volumn 118, Issue 12, 2011, Pages 3445-3446

  Pieri, Lisa ^a   Spolverini, Ambra ^a   Scappini, Barbara ^a   Occhini, Umberto ^b   Birtolo, Silvia ^c   Bosi, Alberto ^a   Albano, Francesco ^d   Fava, Carmen ^e   Vannucchi, Alessandro M ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b IRCCS POLICLINICO SAN DONATO   (Italy)

^c Medical Oncology ASL 3   (Italy)

^d UNIVERSITY OF BARI   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; DASATINIB; IMATINIB;

ADULT; AGED; ALLELE; CHRONIC MYELOID LEUKEMIA; CLONE; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEMALE; GENE; GENE MUTATION; GENETIC SCREENING; HUMAN; JAK2 GENE; LETTER; MALE; PHENOTYPE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; TREATMENT RESPONSE;

EID: 80053181285     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-07-365007     Document Type: Letter

References (5)

1. Makishima H, Jankowska AM, McDevitt MA, et al. CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood. 2011;117(21):e198-e206.
2. Hussein K, Bock O, Theophile K, et al. Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation. Leukemia. 2008;22(5):1059-1062. (Pubitemid 351689890)
3. White HE, Matejtschuk P, Rigsby P, et al. Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. Blood. 2010;116(22):e111-e117.
4. Guglielmelli P, Barosi G, Specchia G, et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood. 2009;114(8):1477-1483.
5. Bocchia M, Vannucchi AM, Gozzetti A, et al. Insights into JAK2-V617F mutation in CML. Lancet Oncol. 2007;8(10):864-866. (Pubitemid 47488062)